Law Enforcement - Use of Force - National Guard Members
Summary
HB1031 would require certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations that cover prescription drugs to also cover prescription weight loss drugs for individuals diagnosed with obesity and at least one comorbid medical condition that can be treated with those drugs. The mandate would apply to individual, group, and blanket policies or contracts issued or delivered in Maryland, as well as HMO contracts issued or delivered in the state.
The bill sets an effective date of January 1, 2026, and applies to policies, contracts, and health benefit plans issued, delivered, or renewed on or after that date. In practical terms, it would add a new required benefit under Maryland insurance law for a defined group of patients, expanding coverage obligations for carriers that already provide prescription drug benefits.
Impact
The bill would add a new section to the Insurance Article, Section 15-839.1, creating a statutory coverage requirement for prescription weight loss medications for qualifying patients with obesity and at least one related comorbidity. This would directly affect insurers, nonprofit health service plans, and HMOs operating in Maryland by requiring them to include this coverage in applicable health plans beginning with renewals or new policies on or after January 1, 2026.
Sentiment
There is no recorded committee testimony, vote, or floor debate in the provided materials, so the bill’s sentiment cannot be measured from discussion history. The available context shows the bill was introduced and then withdrawn by the sponsor in the House, which suggests it did not advance through the legislative process and may have lacked sufficient support, timing, or sponsor interest to continue.
Contention
The main policy issue inherent in the bill is whether insurers should be required to cover prescription weight loss drugs, which can be expensive and may raise premium or utilization concerns for carriers and purchasers. Supporters would likely view the measure as improving access to treatment for obesity and related health conditions, while opponents or skeptics may focus on cost, medical necessity, and the scope of mandated benefits. Because no committee transcript or vote record is provided, specific named objections or supporters are not available.